No Data
Chordia Therapeutics - The international nonproprietary name of the pharmaceutical CTX-712 has been established.
Chordia Therapeutics ＜ 190A ＞ announced on the 20th that the World Health Organization (WHO) has publicly released the International Nonproprietary Name (INN) for the CLK inhibitor drug CTX-712, which the company is developing, as the recommended INN (rINN). In the future, this development product will be referred to as "rogocekib" instead of the development code CTX-712. INN is the universal name for pharmaceuticals worldwide.
Chordia, etc., [stocks with attractive tastes from changes in volume].
Stock closing prices compared to the previous day and volume * <6185> SMN 352,793,344,900 * <7831> Wilco HD 135,184,398,400 * <2588> P Water 308,021,210,3300 * <3079> DVx 92,242,115,200 * <190A> Chordia 222,214,033,300 * <4288> Azugent 56,656,711,00 * <3932> Akatsuki 243,822,821,6400 * <3647> G3 HD 116,436,1400 * <
Chordia Therapeutics Advances Cancer Drug Development
Volume change rate ranking (10 o'clock) - GeoCode, KADOKAWA etc. are ranked.
※In the volume change rate ranking, you can understand the market participants' interest in trends such as speculation by comparing the average volume of the last 5 days with the volume on the delivery day. ■ Top volume change rate [As of 10:32 on November 20] (Comparison with the average volume of the last 5 days) Stock code Company name Volume 5-day average volume Volume change rate Stock price change rate <7357> Geocode 158000 3010.84 342.12% 0.06 38% <9468>
Chordia Research Memo (7): In the fiscal year ending August 2024, there is no recognition of operating income, resulting in an ordinary loss.
■The performance trends of Chordia Therapeutics <190A> 1. Overview of the performance for the fiscal year ending August 2024. There were no business revenues recorded for the fiscal year ending August 2024 (compared to milestone revenue of 2,500 million yen in the previous year), resulting in an operating loss of 1,801 million yen (compared to a profit of 212 million yen in the previous year), an ordinary loss of 1,824 million yen (compared to a profit of 225 million yen), and a net loss for the period of 1,827 million yen (compared to a profit of 223 million yen). Research and development expenses amounted to 1,499 million yen, which is an increase of 497 million yen compared to the previous year.
Chordia Research Memo (6): MALT1 inhibitors have been licensed out to Ono Pharmaceutical Co., Ltd. for conditions exceeding 50 billion yen.
■Chordia Therapeutics <190A> 's development pipeline 2. MALT1 inhibitor (1) Mechanism of action of MALT1 inhibitor and background of early derivation MALT1 inhibitor is a development pipeline expected to have therapeutic effects for refractory lymphoma, achieving early derivation from Ono Pharmaceutical after preclinical trials in 2020. In refractory lymphoma, factors in the T-cell signal or B-cell signal transduction pathway (T-cell receptor CD28, B-cell receptor
No Data
No Data